Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FINASTERIDE vs PROSCAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Finasteride is a competitive 5-alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (DHT), thereby reducing DHT levels in serum and prostate tissue.
Finasteride inhibits 5α-reductase type II, preventing conversion of testosterone to dihydrotestosterone (DHT) in the prostate, reducing prostate volume and improving urinary symptoms.
Benign prostatic hyperplasia (BPH),Male pattern baldness (androgenetic alopecia)
Benign prostatic hyperplasia (BPH) to improve symptoms, reduce risk of acute urinary retention, and reduce need for surgery,Androgenetic alopecia (male pattern hair loss) - off-label for some formulations
1 mg orally once daily for androgenetic alopecia; 5 mg orally once daily for benign prostatic hyperplasia.
5 mg orally once daily.
Terminal elimination half-life is approximately 6-8 hours (range 4-12 hours) in young adults; prolonged to ~8 hours in elderly due to reduced clearance; clinical effect on DHT suppression persists for 24 hours post-dose.
Terminal elimination half-life is 6-8 hours (range 4-12 hours) in young adults; prolonged to 8-10 hours in elderly (≥70 years), but no dose adjustment required. Steady-state reached after 2 weeks dosing.
Metabolized primarily via CYP3A4 in the liver; two inactive metabolites (t-butyl side chain oxidation and glucuronide conjugate).
Primarily metabolized by CYP3A4 to t-butyl side-chain hydroxylated metabolites; minor metabolism by other CYP enzymes.
Renal (39% as metabolites, <0.1% as unchanged drug); fecal (57% as metabolites); biliary elimination contributes to fecal route.
Primarily hepatic metabolism (CYP3A4), metabolites excreted renally (39%) and fecally (57%) as unchanged drug and metabolites.
Approximately 93% bound to plasma proteins (primarily albumin and to a lesser extent alpha-1-acid glycoprotein).
Approximately 90% bound to plasma proteins (albumin and alpha-1-acid glycoprotein).
Volume of distribution = 76 L (approximately 1.0-1.1 L/kg), indicating extensive tissue distribution; crosses blood-brain barrier and partitions into seminal fluid.
Apparent volume of distribution is 1.4 L/kg (range 0.8-2.0 L/kg), indicating extensive tissue distribution (including prostate, seminal vesicles, and skin).
Oral bioavailability is approximately 63% (range 50-80%) due to incomplete absorption and first-pass metabolism; food does not significantly affect bioavailability.
Oral bioavailability is approximately 63-80% (mean 65% from tablet formulation); food does not significantly affect absorption (Cmax decreased by 8%, AUC unchanged).
No dose adjustment required for any level of renal impairment including end-stage renal disease.
No adjustment required for renal impairment; dose adjustment not studied in GFR < 30 m L/min.
No formal studies in hepatic impairment. Caution advised; use not recommended in severe hepatic impairment due to potential accumulation. No specific Child-Pugh based dose recommendations.
No specific guidelines for Child-Pugh A or B; use with caution in severe hepatic impairment.
Not indicated in pediatric patients. Safety and efficacy not established. Avoid use in children.
Not indicated for use in pediatric patients; safety and efficacy not established.
No age-related dose adjustment necessary. Monitor for adverse effects (e.g., sexual dysfunction, mood changes) due to potential increased sensitivity.
No specific dose adjustment required; normal adult dosing recommended.
No FDA black box warning.
Not approved for use in women or children; finasteride is contraindicated in women who are or may become pregnant due to risk of hypospadias in male fetuses.
Risk of high-grade prostate cancer (decreased PSA levels may mask detection),Sexual adverse effects (e.g., decreased libido, erectile dysfunction, ejaculatory disorder) may persist after discontinuation,Increased risk of mood disturbances including depression and suicidal ideation,Not indicated for use in women or children; avoid handling crushed tablets during pregnancy due to risk to male fetus
Increased risk of high-grade prostate cancer (Gleason score 8-10) reported in clinical trials; monitor for urinary obstruction; evaluate for other urological diseases; potential for decreased serum PSA levels; sexual dysfunction (decreased libido, erectile dysfunction, ejaculation disorder) may persist after discontinuation; mood changes including depression; breast cancer risk not established.
Pregnancy (category X; risk of hypospadias in male fetuses),Known hypersensitivity to finasteride or any component of the formulation
Hypersensitivity to finasteride or any component, women who are or may become pregnant, pediatric patients (not indicated).
No significant food interactions reported; finasteride may be taken with or without food. Avoid excessive alcohol consumption as it may worsen BPH symptoms or liver function.
No significant food interactions. Can be taken with or without meals.
Contraindicated in pregnancy. Finasteride inhibits conversion of testosterone to dihydrotestosterone, which is critical for male fetal external genitalia development. Risk of hypospadias and other urogenital malformations if exposed in utero, particularly during first trimester. Pregnancy category X.
Finasteride is contraindicated in pregnancy (Category X). In first trimester, exposure may cause hypospadias in male fetuses due to inhibition of 5α-reductase; second and third trimester risks include ambiguous genitalia in male fetuses. Avoid handling crushed tablets if pregnant.
Not recommended. Finasteride is excreted in human milk; M/P ratio not reported. Risk to nursing infant unknown, but potential for adverse effects on male infant genitalia. Use contraindicated during breastfeeding.
Finasteride is excreted in breast milk in very low amounts (M/P ratio 0.52). Limited data; use caution. Consider alternative therapy, especially in nursing mothers of male infants due to theoretical risk of antiandrogenic effects.
No dose adjustments applicable as finasteride is contraindicated in pregnancy. No pharmacokinetic studies in pregnant women due to ethical concerns.
Not applicable; use is contraindicated in pregnancy. No pharmacokinetic studies in pregnancy; no dose adjustments recommended for any trimester as use is not indicated.
Finasteride inhibits 5α-reductase type II, reducing conversion of testosterone to DHT. Onset of effect in benign prostatic hyperplasia (BPH) requires 6-12 months; for androgenetic alopecia, 3-6 months. Serum PSA levels decrease by approximately 50% after 6 months; multiply PSA by 2 when interpreting. Avoid handling crushed or broken tablets if pregnant or planning to become pregnant due to risk of fetal genital abnormalities. Use with caution in hepatic impairment; contraindicated in women of childbearing potential, children, and patients with hypersensitivity to 5α-reductase inhibitors.
Proscar (finasteride 5 mg) is indicated for benign prostatic hyperplasia (BPH); not interchangeable with Propecia (1 mg) for alopecia. Onset of symptom improvement may take 6-12 months. Monitor serum PSA (multiply by 2 for first 2 years). May cause reversible decrease in libido, ejaculatory dysfunction. Avoid in women of childbearing potential due to teratogenicity (risk of hypospadias).
Take finasteride exactly as prescribed, once daily with or without food.,It may take 3-6 months for hair regrowth or improvement in urinary symptoms; continue therapy as directed even if no immediate benefit is noted.,Report any breast tenderness, enlargement, or lumps; also report any new onset of sexual dysfunction (e.g., decreased libido, erectile dysfunction, ejaculation disorder).,Do not donate blood while taking finasteride and for at least 1 month after stopping, to prevent exposure to a pregnant female.,Women who are pregnant or may become pregnant should not handle crushed or broken tablets due to risk of harm to male fetus.,Serum PSA levels will decrease; inform your healthcare provider that you take finasteride before any PSA test.,Store at room temperature (20-25°C) in a dry place, away from light and moisture.
Take once daily with or without food.,Do not crush or split tablets.,Symptom improvement may take 6 months or longer.,Possible side effects include decreased libido, erectile dysfunction, or decreased semen volume.,Women who are pregnant or may become pregnant should not handle crushed or broken tablets.,Regular monitoring of PSA levels is required during treatment.,Do not donate blood while taking this medication.,Report any breast lumps or testicular pain to your healthcare provider.
"Finasteride, a 5α-reductase inhibitor used for benign prostatic hyperplasia, may inhibit cytochrome P450 3A4 (CYP3A4) isoenzymes. Cyclosporine is primarily metabolized by CYP3A4. Coadministration can lead to reduced cyclosporine clearance, elevated blood concentrations, and increased risk of nephrotoxicity, hypertension, and neurotoxicity."
"Finasteride, a 5α-reductase inhibitor used for benign prostatic hyperplasia, may weakly inhibit CYP3A4, the primary enzyme responsible for sildenafil metabolism. This can lead to a modest reduction in sildenafil clearance, increasing systemic exposure and potentially enhancing both therapeutic effects and adverse events such as headache, flushing, dyspepsia, and hypotension. Clinically, this interaction is generally mild but may require dose adjustment in patients predisposed to sildenafil side effects."
"Finasteride, a 5α-reductase inhibitor, may inhibit CYP3A4-mediated metabolism of netupitant, a neurokinin-1 receptor antagonist primarily metabolized by CYP3A4. This can lead to increased netupitant plasma concentrations, potentially enhancing its adverse effects such as headache, fatigue, or dizziness. Clinically, the combination may require dose adjustment or close monitoring for netupitant toxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FINASTERIDE vs PROSCAR, answered by our medical review team.
FINASTERIDE is a 5-alpha Reductase Inhibitor that works by Finasteride is a competitive 5-alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (DHT), thereby reducing DHT levels in serum and prostate tissue.. PROSCAR is a 5-Alpha Reductase Inhibitor that works by Finasteride inhibits 5α-reductase type II, preventing conversion of testosterone to dihydrotestosterone (DHT) in the prostate, reducing prostate volume and improving urinary symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FINASTERIDE and PROSCAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FINASTERIDE is: 1 mg orally once daily for androgenetic alopecia; 5 mg orally once daily for benign prostatic hyperplasia.. The standard adult dose of PROSCAR is: 5 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FINASTERIDE and PROSCAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FINASTERIDE is classified as Category D/X. Contraindicated in pregnancy. Finasteride inhibits conversion of testosterone to dihydrotestosterone, which is critical for male fetal external genitalia development. Risk of hypos. PROSCAR is classified as Category C. Finasteride is contraindicated in pregnancy (Category X). In first trimester, exposure may cause hypospadias in male fetuses due to inhibition of 5α-reductase; second and third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.